Lead Program
3-V is advancing a novel host-factor program in Chronic Hepatitis C (“HCV”) that is designed to form the backbone of curative antiviral treatment. The target for this program was discovered using 3-V Biosciences’ screening platform and proprietary molecules were invented by 3-V’s internal drug discovery team. These molecules can be used alone or combined with direct-acting antiviral agents to provide treatment regimens that maximize cure rates.
Pipeline and Platform
3-V leverages sophisticated target identification and validation platforms coupled with rigorous drug discovery capabilities to generate novel, host-directed antiviral therapeutics that fulfill our mission of addressing unmet medical needs and improving the lives of patients.